EGFR and non-small cell lung carcinoma: National Comprehensive Cancer Network (NCCN) – In the V1.2011 Guidelines [9], NCCN recommended EGFR mutation testing for the following lung cancer histologies: adenocarcinoma, large cell, and NSCLC, not otherwise specified.  They also recommend the use of erlotinib as first-line therapy for patients who have an EGFR mutation.